TB Activists Call For Broad Access To Otsuka’s Delamanid
This article was originally published in PharmAsia News
Executive Summary
Activists have interrupted a symposium being held by Otsuka at a major international lung conference, calling for the Japanese firm to expand access to delamanid, its new drug for multidrug-resistant tuberculosis (MDR-TB).